Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 10Thoracic 6Head & Neck 4Gastrointestinal 4Gynecologic 3Tumor-Agnostic 2Lymphoid 2Sarcoma 1Other hematologic neoplasm 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Microsatellite Instability 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 297Fluorouracil 272Bevacizumab 235Gemcitabine 234Leucovorin 212Capecitabine 204pembrolizumab 200Nivolumab 157Irinotecan 156Cisplatin 148Specimen Handling 143Magnetic Resonance Spectroscopy 130130-nm albumin-bound paclitaxel 115Paclitaxel 109durvalumab 104Cetuximab 102Radiotherapy 96atezolizumab 92Biopsy 92Drug Therapy 91Albumin-Bound Paclitaxel 78tislelizumab 77Taxes 73Folfox protocol 68lenvatinib 67Carboplatin 65regorafenib 60Blood Specimen Collection 60trifluridine tipiracil drug combination 52Ipilimumab 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
ALT-803 × Gastrointestinal × 1 year × Clear all
NCT06149481 2026-06-05

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07488884 2026-04-29

ResQ108B-PANC

ImmunityBio, Inc.

Phase 1 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

ImmunityBio, Inc.

Phase 2 Active not recruiting
40 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04390399 2025-12-15

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

ImmunityBio, Inc.

Phase 2 Active not recruiting
328 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡